P-glycoprotein targeting: A unique strategy to selectively eliminate immunoreactive T cells

Blood

Volumn 100, Issue 2, 2002, Pages 375-382

  Guimond, Martin ^a   Balassy, Antonia ^a   Barrette, Mélanie ^a   Brochu, Sylvie ^a   Perreault, Claude ^a   Roy, Denis Claude ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIBROMORHODAMINE METHYL ESTER; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC AGENT; GLYCOPROTEIN P; ION CHANNEL; MITOGENIC AGENT; PHOTOSENSITIZING AGENT; RHODAMINE; TH 9402; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0037100450     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0353     Document Type: Article

References (78)

1. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
2. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation
3. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
4. T-cell reconstitution after stemcell transplantation - By which organ
5. Haematopoietic cell transplantation as immunotherapy
6. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection
7. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
8. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings
9. Leukaemic relapse after Campath 1 treated bone marrow transplantation for leukaemia
10. T-cell depletion of HLA-identical transplants in leukemia
11. AntiCD3 epsilon F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
12. Transplantation of anergic histoincompatible bone marrow allografts
13. Deficient cellular immunity-finding and fixing the defects
14. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation
15. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission
16. + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
17. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: A stable equilibrium
18. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect
19. Cytokine cascades in acute graft-versus-host disease
20. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
21. Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis
22. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity
23. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations
24. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: A new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation
25. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69)
26. Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells
27. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
28. Differential activity of P-glycoprotein in normal blood lymphocyte subsets
29. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during aging
30. Multidrug resistance activity in human lymphocytes
31. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives
32. Elimination of chronic myeloid leukemia cells with a novel photodynamic treatment
33. Phase I study of autologous progenitor cell transplantation purged with a photodynamic approach for patients with chronic myeloid leukemia
34. Phototoxicity of some bromine-substituted rhodamine dyes: Synthesis, photophysical properties and application as photosensitizers
35. Specific elimination of anti-host T cell alloreactivity using a photodynamic approach
36. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras
37. Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations
38. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin
39. Relapse after bone marrow transplantation: Evidence for distinct immunological mechanisms between adult and paediatric populations
40. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia
41. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: A method validated by the laboratories of the French Drug Resistance Network
42. A solution to the problems of cytolysis assays with additional applications to other immunological and biochemical assays
43. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
44. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
45. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents
46. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
47. Anergy in peripheral memory CD4(+) T cells induced by low avidity engagement of T cell receptor
48. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy
49. DCs and peripheral T cell tolerance
50. + regulatory T cells induced by chronic retroviral infection
51. Advances in transplantation tolerance
52. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
53. Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells
54. high regulatory cells in human peripheral blood
55. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade
56. Graft-versus-host disease following transplantation of "one log" versus "two log" T-lymphocyte-depleted bone marrow from HLA-identical donors
57. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity
58. Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice
59. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults
60. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex
61. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR
62. + early progenitor cells
63. Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions
64. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
65. Immunodominant minor histocompatibility antigens: The major ones
66. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: Potential role of a veto mechanism
67. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma
68. Fatty acid metabolism in human lymphocytes, I: Time-course changes in fatty acid composition and membrane fluidity during blastic transformation of peripheral blood lymphocytes
69. Early transmembrane events in alloimmune cytotoxic T-lymphocyte activation as revealed by stopped-flow fluorometry
70. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitising agent
71. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux
72. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
73. Donor leukocyte transfusions for leukemic relapse
74. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: Characterization of the critical polymorphic amino acid residues for T-cell recognition
75. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy
76. Identification of clonal T cells in the blood of patients with systemic sclerosis: Positive correlation with response to photopheresis
77. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study
78. Photopheresis for the prevention of rejection in cardiac transplantation